What’s a total !@#$ show these stocks are been at a total loss for ages
Uross03
6 mesi fa
Im in
In at 1.42
Wish me luck (if there’s any)!
Cl1f0
6 mesi fa
VOLUME IS UP⬆️⬆️⬆️
Little spike and looking at the volume there will be another soon. No merger yet but I keep saying we only need to stay above $1 for another week and then we have a high percentage of merger talks thats when we see a rocket. But thats wont be the half of it any of these private companies are looking to merge. And let me tell you they are looking for a shell. Then this is a game changer. It does have to happen to be a game changer but QNCX has the best fit out of all the shells.
1. Xaira Therapeutics
Backing: Launched in April 2024 with $1 billion in committed funding from major firms like ARCH Venture Partners and Foresite Capital.
Why it fits: It is one of the only private biotechs to actually hit the $1 billion funding mark in a single launch. They focus on AI-driven drug discovery, a high-value sector that often attracts significant investor interest.
2. Kailera Therapeutics
Backing: Has raised approximately $1 billion in total private funding as of late 2025/early 2026, including a massive $600 million Series B.
Industry Focus: Obesity (GLP-1) and related metabolic diseases.
Status: While they recently launched an IPO roadshow, many companies in this sector keep a "dual-track" strategy, meaning they evaluate reverse mergers with shells like QNCX simultaneously with IPO plans.
3. Eikon Therapeutics
Backing: Valued at approximately $3.2 billion with significant private backing from investors like T. Rowe Price and Canada Pension Plan Investment Board.
Industry Focus: Advanced microscopy and drug discovery.
Recent Activity: They recently completed an IPO in early 2026, but were long considered a primary candidate for a major public market entry.
idk30008
6 mesi fa
Can we pls see news today !!
Honestly what was the point of clearing debt and doing a 10-1 split, if this was gonna die and if we weren’t gonna stay above $1, hopefully there’s news today or tomorrow, or consider this dead
Analyst101
6 mesi fa
Somethings happening behind closed doors
cianlewis
6 mesi fa
RS completed
the halt is over, let's push
Cl1f0
6 mesi fa
RS 1-for-10 if a merger is on the cards
Ive been doing a little digging and found some previous similar scenarios all available for you to look the Internet. Because Its blown my mind how $5.5m has been paid if they expect to go bankrupt.
Therefore i think there is something in the pipeline. Everything is strictly private and no info to be given.
So asking AI to find me similar scenarios
1. MDGL 2. IRON 3. TECX 4.LH 5. BKNG
The first 3 have similar failed drug trail and then were merged after RS as a shell and not failed company, they are all above $30.72 and MDGL is $527.
I believe we have potential to be sitting pretty here. Im not selling and if it stays above $1 then we look like were have a good start. Pretty sure it has to hold for an actual handshake but this could be one of them gems. Fingers crossed. And for all you holding im with you. NFA
Questa pagina potrebbe includere contenuti generati dalla comunità, di cui Trading 212 non è responsabile. Svolgi sempre le tue ricerche. Trading 212 fornisce un servizio di sola esecuzione e non offre consigli di investimento o gestione del portafoglio.
Compra e vendi IRulya Therapeutics Inc +0,25 $ (0,76%) e oltre 13.000 azioni ed ETF globali
Scarica l'app
Apri account
Potrebbero essere applicate ulteriori commissioni. Visualizza i nostri termini e commissioni.
Compra azioni immediatamente
Scegli l'azienda che preferisci
Seleziona quanto investire
Ottieni le tue azioni in un attimo
Creare ricchezza è un'abitudine. Automatizzala con un pie.
Investi in pies preimpostati o crea il tuo scegliendo tra migliaia di azioni ed ETF.
Scopri di più
Scopri di più
Guarda il video
Arriva a possedere perfino le azioni più costose come quelle di Google, Amazon e Apple
Guarda il video
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Borsa di Londra
Euronext Lisbon
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
Borsa di Londra
Euronext Lisbon
Vedi tutti gli strumenti di trading
Assistenza 24/7
Tempo di risposta medio di 29 secondi
Inizia subito a creare un patrimonio
Unisciti a oltre 5 milioni di utenti
Scarica l'app
Apri account
Scarica l'app per dispositivi mobili
Tutte le statistiche presentate sono globali. Il numero di clienti rappresenta gli Accounts finanziati.
Eccellente
Valutato 4,6 / 5 in base a 106.426 recensioni su
Trustpilot
Valutato 4,6 / 5 in base a 106.426 recensioni su
Trustpilot
Invitato
Excellent
Using Trading 212 has been a very productive and satisfying experience for me. Because the platform is user-friendly, dependable, and simple to navigate, investing is made to be a straightforward and convenient process. I am especially grateful for the user-friendly interface, the useful investment tools, and the capability to track the performance of my portfolio in real time.
Invitato
I have had a fantastic experience with…
have had a fantastic experience with Trading 212. The app is modern, intuitive and incredibly easy to use, making investing feel accessible and straightforward. I particularly appreciate the clear layout, real-time updates and the ability to manage my investments conveniently in one place. The overall experience is smooth, efficient and user-friendly. Whether you are new to investing or more experienced, Trading 212 is an excellent platform that I would happily recommend to others. A brilliant app that makes investing simple!
Invitato
Easy to use and fantastic features
Easy to use and fantastic features
Invitato
Easy to operate app for everyone!
Easy to operate app for everyone!
Invitato
Good platform for all my investments in…
Good platform for all my investments in one place. I have ISA and recently transferred my SIPP. I have a general investment account link to 121 debit card.
Invitato
Awesome service and app
Awesome service and app. Well done guys :)
Invitato
Everything is just so easy to use
Everything is just so easy to use. You can see at a glance how everything is doing.
Invitato
Just a great platform user friendly 0…
Just a great platform user friendly 0 commissions with the pie attachment whats not to like choosing 212 compared to other platforms is literally a no brainer
Invitato
Great app easy to move money in/out…
Great app easy to move money in and out. Good to see how much interest you are making.
Invitato
Easy to use and intuitive
Easy to use and great dashboard to see what’s going on. Moved my stocks and shares ISA from Barclays and not looked back.
Invitato
Easy to use app
Easy to use app, simple processes, good rate of return and regular updates on interest earned.
Invitato
Quick and easy
I found that it was quick and easy to open an account; transfer funds in and out, best of all, to sit back and watch the monies increase.
I would recommend Trading 212
Invitato
App is easy to use
The savings product i have has a good rate of return and I get daily updates. App is really easy to use
Invitato
212 has been a good discovery 6 years ago
212 has been a good discovery. Excellent platform for investment, secure and user friendly. Very good interest rate and good ISA
Invitato
Love it
Love it. Simple for a complete beginner to navigate. Perfect!
Invitato
The best app around
The best app around, so easy to use and navigate… makes investing easy.
Invitato
Easy access to transfer money.
Easy access to transfer money.
Daily updates regarding interest.
Invitato
Great platform
Great platform, easy to navigate and buy/sell. Good statements are available.
Invitato
Trading 212 is very transparent
Trading 212 is very transparent, open and clear with their activities. No outrageous deductions or charges. I recommend it for everyone interested in investment
Invitato
Good and efficient
Good and easy to use with lots of products and investment options
Ecco alcune delle recensioni positive da parte dei clienti.
I nostri premi
Domande frequenti
Qual è il prezzo dell’azione IRulya Therapeutics?
Il prezzo attuale di IRulya Therapeutics è 33,08 $.
Qual è il massimo a 52 settimane di IRulya Therapeutics?
Il massimo a 52 settimane per IRulya Therapeutics è 908 $.
Qual è il minimo a 52 settimane di IRulya Therapeutics?
Il minimo a 52 settimane per IRulya Therapeutics è 15,1 $.
Qual è l’andamento settimanale di IRulya Therapeutics?
Nell’ultima settimana, il prezzo di IRulya Therapeutics è cambiato di 3,28%.
Qual è la performance mensile di IRulya Therapeutics?
Nell’ultimo mese, il prezzo di IRulya Therapeutics è cambiato di 5,52%.
Qual è la performance a 3 mesi di IRulya Therapeutics?
Negli ultimi tre mesi, il prezzo di IRulya Therapeutics è cambiato di 78,43%.
Qual è la performance a 6 mesi di IRulya Therapeutics?
Negli ultimi sei mesi, il prezzo di IRulya Therapeutics è cambiato di 20,73%.
Qual è il rendimento annuale di IRulya Therapeutics?
Nel corso dell’ultimo anno, il prezzo di IRulya Therapeutics è cambiato di -90,91%.